Frances  Arnold net worth and biography

Frances Arnold Biography and Net Worth

Director of Illumina
Dr. Arnold has been a director since 2016. She is the Linus Pauling Professor of Chemical Engineering, Bioengineering and Biochemistry at the California Institute of Technology, where she has been on the faculty since 1986. Dr. Arnold received the Nobel Prize in Chemistry (2018) for pioneering directed enzyme evolution; she has used those methods to create enzymes for alternative energy, chemicals, and medicine. She co-chairs the Presidential Council of Advisors on Science and Technology. She received the Charles Stark Draper Prize of the US National Academy of Engineering in 2011, the US National Medal of Technology and Innovation from President Obama in 2013, and the Millennium Technology Prize in 2016. She has been elected to all three US National Academies of Science, Medicine, and Engineering, and was appointed by Pope Francis to the Pontifical Academy of Sciences in 2019. Dr. Arnold is a co-inventor on 62 issued US patents.

Dr. Arnold currently serves as a director of Alphabet Inc. and of Provivi, a privately held agriculture and pest management company, Aralez Bio, a privately held bioenginieering company, and Resilience, a privately held biopharmaceutical manufacturing company. Dr. Arnold received her B.S. in Mechanical and Aerospace Engineering from Princeton University and her Ph.D. in Chemical Engineering from the University of California, Berkeley. She chairs the Advisory Panel of the David and Lucile Packard Foundation Fellowships in Science and Engineering and is a Trustee of the Gordon Research Conferences.

What is Frances Arnold's net worth?

The estimated net worth of Frances Arnold is at least $1.90 million as of March 28th, 2024. Dr. Arnold owns 15,412 shares of Illumina stock worth more than $1,898,142 as of April 26th. This net worth approximation does not reflect any other investments that Dr. Arnold may own. Learn More about Frances Arnold's net worth.

How do I contact Frances Arnold?

The corporate mailing address for Dr. Arnold and other Illumina executives is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. Illumina can also be reached via phone at (858) 202-4500 and via email at [email protected]. Learn More on Frances Arnold's contact information.

Has Frances Arnold been buying or selling shares of Illumina?

Frances Arnold has not been actively trading shares of Illumina during the past quarter. Most recently, Frances Arnold sold 1,503 shares of the business's stock in a transaction on Monday, May 11th. The shares were sold at an average price of $309.11, for a transaction totalling $464,592.33. Following the completion of the sale, the director now directly owns 9,954 shares of the company's stock, valued at $3,076,880.94. Learn More on Frances Arnold's trading history.

Who are Illumina's active insiders?

Illumina's insider roster includes Alexander Aravanis (SVP), Frances Arnold (Director), Charles Dadswell (SVP), Francis deSouza (CEO), Phillip Febbo (SVP), Jay Flatley (Director), Aimee Hoyt (SVP), Karen Mcginnis (CAO), Robert Ragusa (SVP), Mostafa Ronaghi (SVP), Sam Samad (CFO), Susan Tousi (SVP), and Mark Van Oene (SVP). Learn More on Illumina's active insiders.

Are insiders buying or selling shares of Illumina?

In the last year, Illumina insiders bought shares 1 times. They purchased a total of 7,330 shares worth more than $991,675.70. In the last year, insiders at the life sciences company sold shares 4 times. They sold a total of 1,815 shares worth more than $314,104.60. The most recent insider tranaction occured on February, 22nd when CEO Jacob Thaysen bought 7,330 shares worth more than $991,675.70. Insiders at Illumina own 0.2% of the company. Learn More about insider trades at Illumina.

Information on this page was last updated on 2/22/2024.

Frances Arnold Insider Trading History at Illumina

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/11/2020Sell1,503$309.11$464,592.339,954View SEC Filing Icon  
5/13/2019Sell1,503$307.95$462,848.8510,159View SEC Filing Icon  
3/15/2018Sell250$252.26$63,065.0010,189View SEC Filing Icon  
3/8/2018Sell250$241.50$60,375.0010,439View SEC Filing Icon  
5/25/2017Sell825$174.77$144,185.258,816View SEC Filing Icon  
See Full Table

Frances Arnold Buying and Selling Activity at Illumina

This chart shows Frances Arnold's buying and selling at Illumina by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Illumina Company Overview

Illumina logo
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.
Read More

Today's Range

Now: $123.16
Low: $118.97
High: $123.73

50 Day Range

MA: $131.94
Low: $116.69
High: $143.41

2 Week Range

Now: $123.16
Low: $89.00
High: $213.91

Volume

268,556 shs

Average Volume

1,711,332 shs

Market Capitalization

$19.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19